Biosimilars Forum Wins Global Biosimilars Industry Partner of the Year at Global Generics & Biosimilars Awards

Judges commend the Forum “for the excellent work performed in communicating the benefits of biosimilars” and “tackling the many hurdles in the US biosimilars market”

The Biosimilars Forum was named the 2022 Global Biosimilars Industry Partner of the Year at the Global Generics & Biosimilars Awards, hosted by Generics Bulletin. This award recognizes “outstanding achievements by firms or individuals that work alongside generics and biosimilars manufacturers and suppliers.”

“We are honored to be recognized by Generics Bulletin as the top industry partner that supports biosimilars,” said Juliana M. Reed, executive director of the Biosimilars Forum. “The Forum and our member companies take immense pride promoting safe and effective biosimilars and the legislative, regulatory and reimbursement policies that support them.”

The judges complimented the Forum for its “excellent work performed in communicating the benefits of biosimilars” and “tackling the many hurdles in the US biosimilars market.” In its award submission, the Forum highlighted its many 2022 initiatives, including advancing pro-biosimilar policies, hosting education programs, improving patient access, fighting misinformation, spearheading research, working directly with policymakers and government agencies, media outreach, digital campaigns, and more.

“The strength of the Forum is our member companies, board members and committee co-chairs and committee members,” Reed added. “I am appreciative of the amazing work they do daily to support our industry, and I am honored to be able to work alongside them as we aggressively promote and protect the promise of biosimilars.”

The Biosimilars Forum is a nonprofit trade association that works to advance biosimilars in the United States to bring access and availability to these treatments. For more information on the Forum’s work to increase access to lower-cost biosimilars, visit biosimilarsforum.org.